Pharsight

1. Angiomax patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5196404	SANDOZ	Inhibitors of thrombin	Dec, 2014 (9 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5196404 (Pediatric)	SANDOZ	Inhibitors of thrombin	Jun, 2015 (8 years ago)
US7598343	SANDOZ	Pharmaceutical formulations of bivalirudin and processes of making the same	Jul, 2028 (4 years from now)
US7582727	SANDOZ	Pharmaceutical formulations of bivalirudin and processes of making the same	Jul, 2028 (4 years from now)
US7598343 (Pediatric)	SANDOZ	Pharmaceutical formulations of bivalirudin and processes of making the same	Jan, 2029 (4 years from now)
US7582727 (Pediatric)	SANDOZ	Pharmaceutical formulations of bivalirudin and processes of making the same	Jan, 2029 (4 years from now)

Drugs and Companies using BIVALIRUDIN ingredient

Market Authorisation Date: 15 December, 2000

Treatment: Inhibition of thrombin in a patient

Dosage: INJECTABLE;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
250 mg/vial	01 Sep, 2009	1		27 Jul, 2028	Extinguished

Strength	Dosage	Availability
250MG/VIAL	INJECTABLE;INTRAVENOUS	Prescription

ANGIOMAX family patents

2. Argatroban patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5214052	SANDOZ	Method for dissolving arginineamides and pharmaceutical compositions containing them	Jun, 2014 (9 years ago)

Drugs and Companies using ARGATROBAN ingredient

Market Authorisation Date: 30 June, 2000

Treatment: NA

Dosage: INJECTABLE;INJECTION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 mg/mL, 2.5 mL vials	24 Sep, 2007	1		30 Jun, 2014	Extinguished

Strength	Dosage	Availability
250MG/2.5ML (100MG/ML)	INJECTABLE;INJECTION	Discontinued

ARGATROBAN family patents

3. Arranon patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5424295	SANDOZ	9-β-D-arabinofuranasyl-2-amino-6-methaoxy-9H-purine	Jun, 2017 (6 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5821236	SANDOZ	Tumor treatment with arabinofuranosyl purine derivatives	Feb, 2013 (11 years ago)
US5747472	SANDOZ	Therapeutic methods for using ARA-G derivatives	Feb, 2013 (11 years ago)
US5492897	SANDOZ	Method for treating T-cell lymphoblastic leukemia with ara-G nucleoside derivatives	Feb, 2013 (11 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE)	Oct 28, 2012

Drugs and Companies using NELARABINE ingredient

Market Authorisation Date: 28 October, 2005

Treatment: Treatment of patients with t-cell acute lymphoblastic leukemia and t-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy r...

Dosage: INJECTABLE;INTRAVENOUS

Strength	Dosage	Availability
250MG/50ML (5MG/ML)	INJECTABLE;INTRAVENOUS	Prescription

ARRANON family patents

4. Azopt patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5378703 (Pediatric)	SANDOZ	Sulfonamides useful as carbonic anhydrase inhibitors	Oct, 2012 (11 years ago)
US5461081	SANDOZ	Topical ophthalmic pharmaceutical vehicles	Oct, 2012 (11 years ago)
US5461081 (Pediatric)	SANDOZ	Topical ophthalmic pharmaceutical vehicles	Apr, 2013 (11 years ago)

Drugs and Companies using BRINZOLAMIDE ingredient

Market Authorisation Date: 01 April, 1998

Treatment: Method for delivery

Dosage: SUSPENSION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
1%	SUSPENSION/DROPS;OPHTHALMIC	Prescription

AZOPT family patents

5. Cipro Hc patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5843930	SANDOZ	Method of treating otitis with ciprofloxacin-hydrocortisone suspension	Jun, 2015 (8 years ago)
US5965549	SANDOZ	Ciprofloxacin-hydrocortisone suspension	Jun, 2015 (8 years ago)

Drugs and Companies using CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE ingredient

Market Authorisation Date: 10 February, 1998

Treatment: Method of treating otitis

Dosage: SUSPENSION/DROPS;OTIC

Strength	Dosage	Availability
EQ 0.2% BASE;1%	SUSPENSION/DROPS;OTIC	Prescription

CIPRO HC family patents

6. Ciprodex patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP02799587A	2006-09-21	STRAWMAN LIMITED	Opposition rejected

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6359016	SANDOZ	Topical suspension formulations containing ciprofloxacin and dexamethasone	Aug, 2020 (3 years ago)
US6284804	SANDOZ	Topical suspension formulations containing ciprofloxacin and dexamethasone	Aug, 2020 (3 years ago)
US9345714	SANDOZ	Method of treating middle ear infections	Sep, 2022 (1 year, 7 months ago)
US9149486	SANDOZ	Method of treating middle ear infections	Sep, 2022 (1 year, 7 months ago)
US9402805	SANDOZ	Method of treating middle ear infections	Sep, 2022 (1 year, 7 months ago)
US8846650	SANDOZ	Method of treating middle ear infections	Jun, 2025 (1 year, 1 month from now)

Drugs and Companies using CIPROFLOXACIN; DEXAMETHASONE ingredient

Market Authorisation Date: 18 July, 2003

Treatment: Treatment of acute otitis media; Treatment of acute otitis externa

Dosage: SUSPENSION/DROPS;OTIC

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.3%/0.1%	31 Jul, 2012	1		10 Aug, 2020	Extinguished

Strength	Dosage	Availability
0.3%;0.1%	SUSPENSION/DROPS;OTIC	Prescription

CIPRODEX family patents

7. Durezol patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6114319	SANDOZ	Compositions containing difluprednate	May, 2019 (4 years ago)
US6114319 (Pediatric)	SANDOZ	Compositions containing difluprednate	Nov, 2019 (4 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-26)	Jun 13, 2019
Orphan Drug Exclusivity(ODE)	Jun 13, 2019
M(M-127)	Mar 22, 2016
New Chemical Entity Exclusivity(NCE)	Jun 23, 2013
Pediatric Exclusivity(PED)	Sep 22, 2016
New Indication(I-653)	Jun 13, 2015

Drugs and Companies using DIFLUPREDNATE ingredient

NCE-1 date: 23 September, 2015

Market Authorisation Date: 23 June, 2008

Treatment: NA

Dosage: EMULSION;OPHTHALMIC

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.0005	01 May, 2014	1		18 May, 2019	Extinguished

Strength	Dosage	Availability
0.05%	EMULSION;OPHTHALMIC	Prescription

DUREZOL family patents

8. Exelon patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US4948807	SANDOZ	Phenyl carbamates	Aug, 2012 (11 years ago)
US5602176	SANDOZ	Phenyl carbamate	Feb, 2014 (10 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6316023	SANDOZ	TTS containing an antioxidant	Jan, 2019 (5 years ago)
US6335031	SANDOZ	TTS containing an antioxidant	Jan, 2019 (5 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jun 27, 2016
New Strength(NS)	Aug 31, 2015

Drugs and Companies using RIVASTIGMINE ingredient

Market Authorisation Date: 06 July, 2007

Treatment: Treatment of alzheimer's dementia

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
4.6 mg/24 hr and 9.5 mg/24 hr	27 Apr, 2011	1		08 Jan, 2019	Extinguished
13.3 mg/24 hr	22 Jan, 2013	1	31 Aug, 2015	08 Jan, 2019	Eligible

Strength	Dosage	Availability
9.5MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
4.6MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
13.3MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription

EXELON family patents

9. Focalin patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6528530	SANDOZ	Phenidate drug formulations having diminished abuse potential	Dec, 2015 (8 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6355656	SANDOZ	Phenidate drug formulations having diminished abuse potential	Dec, 2015 (8 years ago)
US5908850	SANDOZ	Method of treating attention deficit disorders with d-threo methylphenidate	Dec, 2015 (8 years ago)

Drugs and Companies using DEXMETHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 November, 2001

Treatment: Method of treating at least one of attention deficit disorder and attention deficit hyperactivity disorder

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2.5 mg	27 Jul, 2004	1	29 Jan, 2007	04 Dec, 2015	Eligible
5 mg and 10 mg	27 May, 2004	1	29 Jan, 2007	04 Dec, 2015	Eligible

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
2.5MG	TABLET;ORAL	Prescription

FOCALIN family patents

10. Focalin Xr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6635284	SANDOZ	Delivery of multiple doses of medications	Dec, 2015 (8 years ago)
US5908850	SANDOZ	Method of treating attention deficit disorders with d-threo methylphenidate	Dec, 2015 (8 years ago)
US7431944	SANDOZ	Delivery of multiple doses of medications	Dec, 2015 (8 years ago)
US6355656	SANDOZ	Phenidate drug formulations having diminished abuse potential	Dec, 2015 (8 years ago)
US5837284	SANDOZ	Delivery of multiple doses of medications	Dec, 2015 (8 years ago)
US6528530	SANDOZ	Phenidate drug formulations having diminished abuse potential	Dec, 2015 (8 years ago)
US6730325	SANDOZ	Multiparticulate modified release composition	Nov, 2019 (4 years ago)
US6228398	SANDOZ	Multiparticulate modified release composition	Nov, 2019 (4 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-80)	Oct 17, 2011
New Dosing Schedule(D-121)	Oct 23, 2012

Drugs and Companies using DEXMETHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 26 May, 2005

Treatment: A method of treating disease amenable to treatment with a phenidate drug by once daily oral administration of an extended release dosage form; Method of treating attention deficit disorder and/or atte...

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
15 mg	14 May, 2007	1	18 Nov, 2013	01 Nov, 2019	Eligible
5 mg, 10 mg and 20 mg	30 Mar, 2007	1	19 Nov, 2013	01 Nov, 2019	Eligible
30 mg	15 Dec, 2010	1	28 Aug, 2013	01 Nov, 2019	Eligible
40 mg	20 Dec, 2010	1	19 Nov, 2013	01 Nov, 2019	Eligible
35 mg	29 Sep, 2011	1	30 Nov, 2016	01 Nov, 2019	Eligible
25 mg	30 Sep, 2011	1	30 Nov, 2016	01 Nov, 2019	Eligible

Strength	Dosage	Availability
35MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
10MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
5MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
30MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
40MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
20MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
15MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
25MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

FOCALIN XR family patents

11. Hycamtin patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5674872	SANDOZ	Treatment of ovarian cancer	Oct, 2014 (9 years ago)
US5674872 (Pediatric)	SANDOZ	Treatment of ovarian cancer	Apr, 2015 (9 years ago)
US8158645	SANDOZ	Compound, corresponding compositions, preparation and/or treatment methods	Dec, 2024 (7 months from now)

Drugs and Companies using TOPOTECAN HYDROCHLORIDE ingredient

Market Authorisation Date: 28 May, 1996

Treatment: Treatment of metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy

Dosage: INJECTABLE;INJECTION; CAPSULE;ORAL

Strength	Dosage	Availability
EQ 4MG BASE/VIAL	INJECTABLE;INJECTION	Prescription
EQ 0.25MG BASE	CAPSULE;ORAL	Prescription
EQ 1MG BASE	CAPSULE;ORAL	Prescription

HYCAMTIN family patents

12. Lescol Xl patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6242003	SANDOZ	Organic compounds	Apr, 2020 (4 years ago)
US6242003 (Pediatric)	SANDOZ	Organic compounds	Oct, 2020 (3 years ago)

Drugs and Companies using FLUVASTATIN SODIUM ingredient

Market Authorisation Date: 06 October, 2000

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
80 mg	15 Mar, 2007	1		13 Apr, 2020	Extinguished

Strength	Dosage	Availability
EQ 80MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription

LESCOL XL family patents

13. Lotrel patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6162802	SANDOZ	Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor	Dec, 2017 (6 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6162802	SANDOZ	Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor	Dec, 2017 (6 years ago)

Drugs and Companies using AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE ingredient

Market Authorisation Date: 03 March, 1995

Treatment: Treatment of cardiovascular disorders; Method of treating hypertension

Dosage: CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2.5 mg/10 mg 5 mg/10 mg 5 mg/20 mg 10 mg/20 mg	09 Jun, 2004	1	18 Mar, 2007	19 Dec, 2017	Eligible
5 mg/40 mg and 10 mg/40 mg	17 Nov, 2006	1	29 Jul, 2010	19 Dec, 2017	Eligible

Strength	Dosage	Availability
EQ 5MG BASE;20MG	CAPSULE;ORAL	Prescription
EQ 5MG BASE;10MG	CAPSULE;ORAL	Prescription
EQ 10MG BASE;40MG	CAPSULE;ORAL	Prescription
EQ 2.5MG BASE;10MG	CAPSULE;ORAL	Prescription
EQ 5MG BASE;40MG	CAPSULE;ORAL	Prescription
EQ 10MG BASE;20MG	CAPSULE;ORAL	Prescription

LOTREL family patents

14. Qoliana patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7265117	SANDOZ	Topical brimonidine tartrate formulations that lack chlorine dioxide	Aug, 2025 (1 year, 3 months from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 22 May, 2006

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.15%	SOLUTION/DROPS;OPHTHALMIC	Prescription

QOLIANA family patents

15. Reclast patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP05012711A	2013-06-26	Taylor Wessing LLP	Revoked
EP05012711A	2013-06-25	Sanovel IIaç San. ve Tic. A.S.	Revoked
EP05012711A	2013-06-25	Teva Pharmaceutical Industries LTD.	Revoked
EP05012711A	2013-06-20	Actavis PTC ehf	Revoked
EP05012711A	2013-03-18	Generics [UK] Limited	Revoked

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US4939130	SANDOZ	Substituted alkanediphosphonic acids and pharmaceutical use	Sep, 2012 (11 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US4939130 (Pediatric)	SANDOZ	Substituted alkanediphosphonic acids and pharmaceutical use	Mar, 2013 (11 years ago)
US8052987	SANDOZ	Method of administering bisphosphonates	Oct, 2023 (6 months ago)
US7932241	SANDOZ	Pharmaceutical products comprising bisphosphonates	Feb, 2028 (3 years from now)
US7932241 (Pediatric)	SANDOZ	Pharmaceutical products comprising bisphosphonates	Aug, 2028 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-595)	May 29, 2012
New Indication(I-581)	Dec 19, 2011
New Indication(I-584)	Mar 15, 2012

Drugs and Companies using ZOLEDRONIC ACID ingredient

Market Authorisation Date: 16 April, 2007

Treatment: Treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis; Treatment of osteoporosis in postmenopausal women

Dosage: INJECTABLE;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.05 mg/mL, 100 mL vial	29 Aug, 2008	1		02 Sep, 2012	Extinguished

Strength	Dosage	Availability
EQ 5MG BASE/100ML	INJECTABLE;INTRAVENOUS	Prescription

RECLAST family patents

16. Ritalin La patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5837284	SANDOZ	Delivery of multiple doses of medications	Dec, 2015 (8 years ago)
US6635284	SANDOZ	Delivery of multiple doses of medications	Dec, 2015 (8 years ago)
US7431944	SANDOZ	Delivery of multiple doses of medications	Dec, 2015 (8 years ago)
US6228398	SANDOZ	Multiparticulate modified release composition	Nov, 2019 (4 years ago)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 April, 2004

Treatment: Treatment of attention deficit hyperactivity disorder using a dosage form which provides once-daily oral administration of a phenidate drug; Treatment of attention deficit hyperactivity disorder using...

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
10 mg	21 May, 2007	1		01 Nov, 2019	Extinguished
20 mg, 30 mg and 40 mg	21 Aug, 2006

Strength	Dosage	Availability
20MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
30MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
40MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
10MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

RITALIN LA family patents

17. Timolol Maleate patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6174524	SANDOZ	Gelling ophthalmic compositions containing xanthan gum	Mar, 2019 (5 years ago)
US6174524 (Pediatric)	SANDOZ	Gelling ophthalmic compositions containing xanthan gum	Sep, 2019 (4 years ago)

Drugs and Companies using TIMOLOL MALEATE ingredient

Market Authorisation Date: 21 October, 1998

Treatment: NA

Dosage: SOLUTION, GEL FORMING/DROPS;OPHTHALMIC

TIMOLOL MALEATE family patents

18. Travatan Z patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5510383	SANDOZ	Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension	Aug, 2013 (10 years ago)
US5889052	SANDOZ	Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension	Dec, 2014 (9 years ago)
US8388941	SANDOZ	Self preserved aqueous pharmaceutical compositions	Sep, 2027 (3 years from now)
US8323630	SANDOZ	Self-preserved aqueous pharmaceutical compositions	Sep, 2027 (3 years from now)
US8268299	SANDOZ	Self preserved aqueous pharmaceutical compositions	Oct, 2029 (5 years from now)

Drugs and Companies using TRAVOPROST ingredient

Market Authorisation Date: 21 September, 2006

Treatment: Method for treating glaucoma and ocular hypertension

Dosage: SOLUTION/DROPS;OPHTHALMIC

TRAVATAN Z family patents

19. Vivelle-dot patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5474783	SANDOZ	Solubility parameter based drug delivery system and method for altering drug saturation concentration	Dec, 2012 (11 years ago)
US5958446	SANDOZ	Solubility parameter based drug delivery system and method for altering drug saturation concentration	Dec, 2012 (11 years ago)
US6024976	SANDOZ	Solubility parameter based drug delivery system and method for altering drug saturation concentration	Jan, 2014 (10 years ago)
US5656286	SANDOZ	Solubility parameter based drug delivery system and method for altering drug saturation concentration	Aug, 2014 (9 years ago)

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 03 May, 2002

Treatment: NA

Dosage: SYSTEM;TRANSDERMAL

VIVELLE-DOT family patents

20. Zofran patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5854270	SANDOZ	Oral compositions containing ondansetron	Nov, 2015 (8 years ago)
US5854270 (Pediatric)	SANDOZ	Oral compositions containing ondansetron	May, 2016 (7 years ago)

Drugs and Companies using ONDANSETRON HYDROCHLORIDE ingredient

Market Authorisation Date: 24 January, 1997

Treatment: Relief of nausea and vomiting

Dosage: SOLUTION;ORAL

ZOFRAN family patents

21. Zofran Odt patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5955488	SANDOZ	Freeze-dried compositions	Nov, 2015 (8 years ago)
US6063802	SANDOZ	Ondansetron freeze-dried dosage form compositions for oral administration	Nov, 2015 (8 years ago)
US5955488 (Pediatric)	SANDOZ	Freeze-dried compositions	May, 2016 (7 years ago)
US6063802 (Pediatric)	SANDOZ	Ondansetron freeze-dried dosage form compositions for oral administration	May, 2016 (7 years ago)

Drugs and Companies using ONDANSETRON ingredient

Market Authorisation Date: 27 January, 1999

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

Application	Filing Date	Opposition Party	Legal Status

EP07842925A	2016-03-17	Pohlman, Sandra M.	Patent maintained as amended
EP07842914A	2012-08-02	Pohlman, Sandra M.	Patent maintained as amended
EP07842914A	2012-08-02	ALLERGAN, INC.	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8268299	March, 2017	FWD Entered	Alcon Research, Ltd.	Argentum Pharmaceuticals LLC
US8268299	July, 2013	Terminated-Settled	ALCON RESEARCH, LTD.	Apotex Corp.
US8323630	July, 2013	Terminated-Settled	ALCON RESEARCH, LTD.	Apotex Corp.
US8388941	July, 2013	Terminated-Settled	Alcon Research, Ltd.	Apotex Corp.

Strength	Dosage	Availability
EQ 0.25% BASE	SOLUTION, GEL FORMING/DROPS;OPHTHALMIC	Prescription
EQ 0.5% BASE	SOLUTION, GEL FORMING/DROPS;OPHTHALMIC	Prescription

Strength	Dosage	Availability
0.05MG/24HR	SYSTEM;TRANSDERMAL	Prescription
0.0375MG/24HR	SYSTEM;TRANSDERMAL	Prescription
0.1MG/24HR	SYSTEM;TRANSDERMAL	Prescription
0.025MG/24HR	SYSTEM;TRANSDERMAL	Prescription
0.075MG/24HR	SYSTEM;TRANSDERMAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2 mg/mL, 2 mL vials (Preservative-free)
2 mg/mL, 20 mL vials
4 mg/5 mL	20 Dec, 2004	1	26 Dec, 2006	20 May, 2016	Eligible
4 mg, 8 mg, 16 mg and 24 mg

Strength	Dosage	Availability
4MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
8MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued

Pharsight

Sandoz patents expiration

1. Angiomax patents expiration

ANGIOMAX family patents

2. Argatroban patents expiration

ARGATROBAN family patents

3. Arranon patents expiration

ARRANON family patents

4. Azopt patents expiration

AZOPT family patents

5. Cipro Hc patents expiration

CIPRO HC family patents

6. Ciprodex patents expiration

CIPRODEX family patents

7. Durezol patents expiration

DUREZOL family patents

8. Exelon patents expiration

EXELON family patents

9. Focalin patents expiration

FOCALIN family patents

10. Focalin Xr patents expiration

FOCALIN XR family patents

11. Hycamtin patents expiration

HYCAMTIN family patents

12. Lescol Xl patents expiration

LESCOL XL family patents

13. Lotrel patents expiration

LOTREL family patents

14. Qoliana patents expiration

QOLIANA family patents

15. Reclast patents expiration

RECLAST family patents

16. Ritalin La patents expiration

RITALIN LA family patents

17. Timolol Maleate patents expiration

TIMOLOL MALEATE family patents

18. Travatan Z patents expiration

TRAVATAN Z family patents

19. Vivelle-dot patents expiration

VIVELLE-DOT family patents

20. Zofran patents expiration

ZOFRAN family patents

21. Zofran Odt patents expiration

ZOFRAN ODT family patents

Related content